TY - JOUR
T1 - Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production
AU - Deshmukh, Hitesh S.
AU - McLachlan, Anne
AU - Atkinson, Jeffrey J.
AU - Hardie, William D.
AU - Korfhagen, Thomas R.
AU - Dietsch, Maggie
AU - Liu, Yang
AU - Di, Peter Y.P.
AU - Wesselkamper, Scott C.
AU - Borchers, Michael T.
AU - Leikauf, George D.
PY - 2009/11/1
Y1 - 2009/11/1
N2 - Rationale: Induced mainly by cigarette smoking, chronic obstructive pulmonary disease (COPD) is a global public health problem characterized by progressive difficulty in breathing and increased mucin production. Previously, we reported that acrolein levels found in COPD sputum could activatematrixmetalloproteinase-9 (MMP9). Objectives: To determine whether acrolein increases expression and activity of MMP14, a critical membrane-bound endopeptidase that can initial aMMP-activation cascade. Methods: MMP14 activity and adduct formation were measured following direct acrolein treatment. MMP14 expression and activity was measured in human airway epithelial cells. MMP14 immunohistochemistry was performed with COPD tissue, and in acrolein- or tobacco-exposed mice. Measurements and Main Results: In a cell-free system, acrolein, in concentrations equal to those found in COPD sputum, directly adducted cysteine 319 in the MMP14 hemopexin-like domain and activated MMP14. Incells, acrolein increased MMP14 activity, which was inhibited by a proprotein convertase inhibitor, hexa-D-arginine. In the airway epithelium of COPD subjects, immunoreactive MMP14 protein increased. In mouse lung, acrolein or tobacco smoke increased lung MMP14 activity and protein. In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Decreasing the MMP14 protein and activity in vitro by small interfering (si)RNA to MMP14 diminished the acrolein-induced MUC5AC transcripts. In acrolein-exposedmice or transgenic mice with lung-specific transforming growth factor-a (an EGFR ligand) expression, lung MMP14 and MUC5AC levels increased and these effects were inhibited by a EGFR inhibitor, erlotinib. Conclusions: Taken together, these findings implicate acrolein-induced MMP14 expression and activity inmucin production in COPD.
AB - Rationale: Induced mainly by cigarette smoking, chronic obstructive pulmonary disease (COPD) is a global public health problem characterized by progressive difficulty in breathing and increased mucin production. Previously, we reported that acrolein levels found in COPD sputum could activatematrixmetalloproteinase-9 (MMP9). Objectives: To determine whether acrolein increases expression and activity of MMP14, a critical membrane-bound endopeptidase that can initial aMMP-activation cascade. Methods: MMP14 activity and adduct formation were measured following direct acrolein treatment. MMP14 expression and activity was measured in human airway epithelial cells. MMP14 immunohistochemistry was performed with COPD tissue, and in acrolein- or tobacco-exposed mice. Measurements and Main Results: In a cell-free system, acrolein, in concentrations equal to those found in COPD sputum, directly adducted cysteine 319 in the MMP14 hemopexin-like domain and activated MMP14. Incells, acrolein increased MMP14 activity, which was inhibited by a proprotein convertase inhibitor, hexa-D-arginine. In the airway epithelium of COPD subjects, immunoreactive MMP14 protein increased. In mouse lung, acrolein or tobacco smoke increased lung MMP14 activity and protein. In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Decreasing the MMP14 protein and activity in vitro by small interfering (si)RNA to MMP14 diminished the acrolein-induced MUC5AC transcripts. In acrolein-exposedmice or transgenic mice with lung-specific transforming growth factor-a (an EGFR ligand) expression, lung MMP14 and MUC5AC levels increased and these effects were inhibited by a EGFR inhibitor, erlotinib. Conclusions: Taken together, these findings implicate acrolein-induced MMP14 expression and activity inmucin production in COPD.
KW - Acrolein
KW - Chronic obstructive pulmonary disease
KW - Cigarette smoke
KW - Erlotinib
KW - Mucous cell metaplasia
UR - http://www.scopus.com/inward/record.url?scp=70350435126&partnerID=8YFLogxK
U2 - 10.1164/rccm.200903-0328OC
DO - 10.1164/rccm.200903-0328OC
M3 - Article
C2 - 19661247
AN - SCOPUS:70350435126
SN - 1073-449X
VL - 180
SP - 834
EP - 845
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 9
ER -